Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

Investment income was $2.0 million during fiscal year 2008 compared to $2.5 million during fiscal year 2007. This $0.5 million decrease was due to lower rates of return on the average invested cash balances during 2008.

Pharmasset reported a net loss attributable to common stockholders of $54.7 million, or $2.51 per share, as compared to a net loss attributable to common stockholders of $6.8 million, or $0.46 per share for the same period in 2007.

    Calendar Year 2009 Anticipated Milestones

    -- Meet with FDA in January 2009 to discuss phase 2b and future trials of
       R7128
    -- Roche initiates phase 2b study of R7128 in first quarter of 2009
    -- Complete enrollment of clevudine registration trials end of first
       quarter of 2009
    -- File IND for PSI-7851 in first quarter of 2009
    -- Report end of treatment data from 28 day add-on study with R7128 in
       non-responder, HCV genotype 2 and genotype 3 patients in first quarter
       of 2009
    -- Report interim results from INFORM-1 trial in first half of 2009
    -- Report end of treatment results from 28 day add-on study with R7128 in
       treatment naive, HCV genotype 1 patients around mid-year 2009
    -- Report phase 1 data with PSI-7851 in second half of 2009

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ALTO, Calif. , Sept. 30, 2014 /PRNewswire/ ... investment group focused on supporting promising emerging biotech, ... has been named the Top Angel Investment Group ... Insights as the best performer out of 370 ... included: historical performance, network strength (connections), selection aptitude ...
(Date:9/30/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... a finalist in the Diagnostics & Research Tools ... Awards, sponsored by CONNECT. CONNECT, a regional program that ... sciences products in San Diego County ...
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
Breaking Medicine Technology:Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 2Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 3Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3
... CHICAGO, May 16, 2012 /PRNewswire-iReach/ -- Chronic ... most common causes of persistent, debilitating back pain. Chicago ... compromised his livelihood and soured his outlook on life. ... many doctors, he finally found relief with non-surgical treatment ...
... The sleep apnea diagnostics devices market has witnessed ... caused by improved awareness. The market is currently in ... largely dependent on the degree of awareness of sleep ... Frost & Sullivan ( http://www.patientmonitoring.frost.com ), Strategic Analysis ...
Cached Medicine Technology:The Illinois Back Institute Helps Patient Beat Debilitating Back Pain 2Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan 2Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan 3
(Date:9/30/2014)... Jose, California (PRWEB) September 30, 2014 ... are organic compounds, which are mixed with animal feed ... weight gain, and improve gut health and digestion. Amidst ... milk, eggs and meat across the globe, the need ... and aquaculture sectors is on the rise, thereby driving ...
(Date:9/30/2014)... Eastern Finland shows that dietary polyunsaturated fatty acids may ... of polyunsaturated fatty acids include fish, vegetable oils, and ... & Vascular Biology , an esteemed journal of the ... an association between the consumption of saturated fats and ... mere reduction of saturated fats from the diet does ...
(Date:9/30/2014)... Amy Norton ... News) -- Long-acting contraceptive devices should be the first ... from the American Academy of Pediatrics state. Although ... pills, two other forms of contraception -- intrauterine devices ... according to the academy. And they should be ...
(Date:9/30/2014)... Visit Pam and Steve’s quiet home in ... find a loving couple facing the most monumental challenge ... , Steve was diagnosed with ALS – more commonly ... before the couple’s second wedding anniversary. Pam is ... “Care, Support & ALS,” that’s part of ...
(Date:9/30/2014)... Neuromuscular and central nervous system ... States and worldwide. It is estimated that 50,000-60,000 ... year, adding to the more than one million ... people in the US are affected by Multiple ... statistics the 2.4 percent of the US population ...
Breaking Medicine News(10 mins):Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Dietary polyunsaturated fatty acids linked to smaller risk of coronary heart disease 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3
... Research, Inc.,(Scimitar) issues a review of StatSure Diagnostic ... for Investors Seeking,to Participate In a Proprietary Point-of-Care ... website: http://www.scimitarequity.com . ABOUT STATSURE ... development,manufacture and marketing of rapid immunoassay tests for ...
... Valve Repair Product Portfolio, MINNEAPOLIS, Oct. ... ), manufacturer and marketer of state-of-the-art cardiac,surgery ... and Drug,Administration (FDA) clearance for the ATS ... the next in a series of,mitral valve ...
... to Provide Funding and Support for "Patient Navigator,Program" ... Everett, Washington, EVERETT, Wash., Oct. 25 ... new Patient Navigator Program at,the Providence Regional Cancer ... one part of a strategic nationwide effort to,significantly ...
... for interviews, OAKLAND, Calif., Oct. 25 ... volunteer,registered nurses through its Registered Nurse Response Network ... the spreading disaster,created by wildfires in the region. ... to shelters in San Diego,County in response to ...
... House Republican Whip,Roy Blunt (Mo.) issued the following ... children,s health program created by,Republicans to expand taxpayer-funded care ... in some cases, not even in this country legally:, ... take our concerns to heart and,come back with an ...
... 25 Darwin,Professional Underwriters, Inc. (Darwin) (NYSE: ... its third quarter 2007 financial results following the,close ... conference call to,discuss the company,s third quarter 2007 ... 2007 at 8:00 a.m. Eastern Time. (Logo: ...
Cached Medicine News:Health News:StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) Review Issued By Scimitar Equity Research, Inc. 2Health News:ATS Medical Receives FDA Clearance for ATS Simulus Semi-Rigid Annuloplasty Ring 2Health News:ATS Medical Receives FDA Clearance for ATS Simulus Semi-Rigid Annuloplasty Ring 3Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 2Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 3Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 5Health News:CNA/NNOC Nurse Volunteers Deployed to Southern California Firestorm 2Health News:Darwin to Announce Third Quarter 2007 Financial Results 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: